Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group - Seite 2

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “This is a major achievement for our Company as we will no longer have any further future financial obligations towards the Alter Pharma Group, and moreover, it resolves any potential risks in relation to conflicts of interest and related party transactions. It is also financially attractive and enables us to fully focus on executing our business strategy. We look forward to further progressing our innovative pipeline and to bringing our product candidates to underserved patient populations, with the goal to change and improve therapy outcomes and add value to all stakeholders of the healthcare system.”

For further information on the renegotiated and unwound agreement with the Alter Pharma Group, please consult the public announcement in accordance with Article 7:97, §4/1 of the Code of Companies and Associations, which is available on the Hyloris website: https://investors.hyloris.com/corporate-governance/#docu.

About the arrangements with the Alter Pharma Group

The renegotiated and unwound agreements announced today are related to the arrangements outlined below that Hyloris Pharmaceuticals had with the subsidiaries of the Alter Pharma Group, including Generic Specialty Pharma, Nordic Specialty Pharma, Stasisport Pharma and Neogen Developments.

These arrangements included licensing agreements, asset purchase agreements, development agreements and patent and know-how agreements. The products associated with these arrangements were Maxigesic IV, HY-075, Fusidic Acid Cream, HY-038, and HY-028 (no longer in development since prior to the IPO in 2020). Under the various transactional agreements between Hyloris and the subsidiaries of the Alter Pharma Group, Hyloris was required to pay these entities a combination of licensing fees, milestone payments and royalty payments.

About Hyloris Pharmaceuticals

Hyloris is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients, physicians, and the healthcare systems. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad, patented portfolio of 13 reformulated and repurposed value-added products that have the potential to offer significant advantages over currently available alternatives. Two products are currently commercialised with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.